The CEO is appointed by the Board of Directors and leads the Company in accordance with the guidelines and instructions adopted by the Board. The CEO appoints a Management Group. The Management Group consisted of five people in addition to the CEO during the year.
Holdings in Enzymatica December 31, 2019
Born 1969. Acting CEO. Chief Financial Officer since January 2018.
Therese has extensive experience as CFO. Most recently, Therese was CFO and deputy CEO of the Procurator Group, one of the leading Nordic wholesalers in protective clothing, sanitary goods and office materials.
Before that, Therese worked at MTG (including CDON and TV Shop) and Bravida Syd. In addition to responsibility for financial issues, Therese has been responsible for HR, legal and strategic IT issues.
Education: M.Sc. Econ Lund University and B.A. in education.
Holdings in Enzymatica: 100,000 shares. 250,000 personnel options warrants 110 000
Born 1961. COO & Senior Director Growth since June 2017
Claus Egstrand has previously held positions as Head of Europe for MSD Consumer Care at the pharmaceutical company Merck & Co, as well as Vice President, General Manager Medsurg Europe for the medical technologies firm Stryker Corporation.
Claus has served as Senior Vice President Consumer Healthcare for Latin America, Africa, Asia, Japan and Australia at the pharmaceutical company Pfizer, Vice President and head of global marketing for the smoking cessation product Nicorette at the pharmaceutical company Pharmacia, as well as CEO of Johnson&Johnson/Merck Pharmaceuticals operations in France. His most recent position was Group President, International at Hologic Corp.
Education: MBA, Business School of Copenhagen
Holdings in Enzymatica: 12,000 shares, 750,000 personnel options, 500 000 warrants
Born 1965. Director Innovation since 2011.
Cofounder of Enzymatica. Ulf has over 20 years of experience in various management positions in sales and marketing in the pharmaceutical industry, including Novo Nordisk, Astra Zeneca and ALK. His extensive experience includes all phases of strategic global commercialization of medical devices and pharmaceuticals.
Other directorships: Board member of Idogen AB.
Education: M.Sc. Econ.
Holdings in Enzymatica: 1,964 668 shares, 40,000 personnel options 100 000 warrants
Born 1966. Director of Quality Assurance
Åsa Anderlind comes most recently from QPharma, where she was responsible for GMP training and internal audits. Before that she was Director of Quality Assurance at Euro Diagnostica AB and Wieslab AB (subsidiary) for ten years. She has also held various quality assurance positions at BioInvent, Ferring and Biopool.
Education: Master of Science in Biology , Lund University
Holdings in Enzymatica: 0 shares 37 500 warrants
Born 1970.Director Global Project Management since 2017.
Johan has previously held the position of factory manager at Biomet (now Zimmer Biomet), and held various positions in their European operations.
Johan’s most recent position was as Deputy CEO and Chief Operating Officer for the Agellis Group, which develops, manufactures and markets measuring instruments and monitoring equipment for the global metals industry. Johan has previously held executive positions in supply chain management and product development at companies such as Volvo Excavators AB and Precise Biometrics AB.
Education: BS in mechanical engineering, Faculty of Engineering, Lund University (LTH), as well as university studies in business.
Holdings in Enzymatica: 110,000 shares, 250,000 personnel options 75 000 warrants
Born: 1955. Head of Corporate Communications – co-opted member of management.
Carl-Johan has been engaged as Head of Corporate Communications since September 2017. Carl-Johan has also served as Chief Information Officer for the pharmaceutical companies Kabi and Kabi Pharmacia, Deputy CEO for Procordia EuroCentre in Brussels and Director of Corporate Communications and together with the CFO, responsible for Investor Relations at Atlas Copco. Carl-Johan currently serves as an advisor in strategic communication to corporate management.
Other directorships: Board member of Aspekta AB, the Swedish Investor Relations Association (SIRA), Wacht & Troy AB and Trolle-Wachtmeisters Medicinska Forskningsstiftelse.
Education: BA in business administration and political science.
Holdings in Enzymatica: 250 000 shares 100 000 warrants
Born 1968. Director of Operations since 2021
Malin Richter came from McNeil to Enzymatica in January 2021. Her most recent role there was Head of Plan, which included planning, purchasing direct materials and launching new products (roll-outs). Malin's first line position was in 1999 as Business Unit Manager Operations at Pharmacia. Since then, Malin has held several management positions in Operations and Supply Chain at Pharmacia, Pfizer and McNeil and then worked with products such as Nicorette, Treo and Microlax. Malin has a global experience working with OTC drugs in Operations and Supply Chain.
Education: Master of Science, Mechanical Engineering, Lunds Tekniska Högskola
MBA, General Management, Lunds Universitet
Holdings in Enzymatica: 0
Född 1977 Commercial Director
Kristoffer will join Enzymatica from L’Oréal as of February 1st, where he held the position as Brand Director in charge of two of the leading dermocosmetics brands La Roche-Posay and CeraVe in the Nordics. Kristoffer has 17 years’ of life science and consumer healthcare experience from companies such as L’Oréal, Ferrosan, Reckitt Benckiser and AAK. The experience spans brand and product marketing, sales and key account management driving the development of strong global brands, retailers and distributors worldwide.
MSc. in Business Administration Stockholm School of Economics
Holdings in Enzymatica: 0
Born 1967. Director Regulatory Affairs since November 2016
Ann-Christine has over 25 years of experience from various expert and management positions within regulatory affairs in the medical device industry, including companies such as Siemens, Medtronic, EuroDiagnostica and also start-up companies such as BoneSupport. Her experience includes all phases of global regulatory strategies, including executing strategies for market access for medical devices within all classes.
Education: Master of Science in Material Science, Royal Institute of Technology, Stockholm
Holdings in Enzymatica: 0